Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;3(15):207.
doi: 10.3978/j.issn.2305-5839.2015.05.13.

Recent advances in the treatment of melanoma with BRAF and MEK inhibitors

Eva Muñoz-Couselo  1 , Jesús Soberino García  1 , José Manuel Pérez-García  1 , Vanesa Ortega Cebrián  1 , Javier Cortés Castán  1
Affiliations
Review

Recent advances in the treatment of melanoma with BRAF and MEK inhibitors

Eva Muñoz-Couselo et al. Ann Transl Med. 2015 Sep.

Abstract

Selective inhibition of the mitogen activated protein kinase (MAPK) pathway with either BRAF or MEK inhibition has emerged as the key component for the treatment of BRAF-mutant metastatic melanoma. New evidence from several phase III trials suggests that the combination of BRAF and MEK inhibitors improves tumor response rate and progression-free survival (PFS). Some of the serious adverse events, in particular, the incidence of cutaneous squamous cell carcinoma seen with the monotherapy treatment with a BRAF inhibitor are attenuated with combination therapy, whereas milder side effects such as pyrexia can be more common with combination therapy. Although dose reductions and dose interruptions are slightly more common with combination therapy, overall data supports the notion that combination therapy is safe and improves the outcomes for metastatic melanoma patients compared to single agent BRAF inhibitors.

Keywords: BRAF inhibitor; BRAF mutation; MEK inhibitor; Metastatic melanoma; NRAS mutation.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
MAPK pathway. RTK, receptor tyrosine kinase; GTP, guanosine triphosphate; ERK, extracellular signal-related kinase; MAP, mitogen-activated protein; MAPK, mitogen-activated protein kinase.
Figure 2
Figure 2
Mechanisms of resistance to BRAF inhibitors.
Figure 3
Figure 3
Acquired resistance to BRAF inhibitors.
See this image and copyright information in PMC

References

    1. Heideman DA, Lurkin I, Doeleman M, et al. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn 2012;14:247-55. - PubMed
    1. Devitt B, Liu W, Salemi R, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011;24:666-72. - PubMed
    1. Eskandarpour M, Huang F, Reeves KA, et al. Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Int J Cancer 2009;124:16-26. - PubMed
    1. Eskandarpour M, Kiaii S, Zhu C, et al. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 2005;115:65-73. - PubMed
    1. Glitza IC, Davies MA. Genotyping of cutaneous melanoma. Chin Clin Oncol 2014;3:27. - PMC - PubMed